DTR-P. aeruginosa Treatment
DTR-Pseudomonas aeruginosa: Applying Best Practices in Complex Clinical Scenarios

Released: November 16, 2023

Emily Heil
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Trevor Van Schooneveld
Trevor Van Schooneveld, MD, FSHEA, FACP
Laila Woc-Colburn
Laila Woc-Colburn, MD

Activity

Progress
1
Course Completed

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including:

  • Mechanisms of β-lactam resistance
  • Effect of resistance mechanism on susceptibility to antipseudomonal agent
  • 2023 IDSA guidance recommendations 
  • Activity against newer antipseudomonal β-lactams in the United States
  • The latest clinical data by antimicrobial regimen:
    - Ceftolozane/tazobactam
    - Ceftazidime/avibactam
    - Imipenem/cilastatin/relebactam
    - Cefiderocol
  • Applying antimicrobial stewardship principles